Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic to Help Organon Revive Shelved Drug Candidates

NEW YORK, April 21 (GenomeWeb News) - Gene Logic and Organon have signed a drug-repositioning pact and plan to seek alternative paths for "multiple" drug candidates Organon had previously shelved.

 

As part of the agreement, if the research yields new uses for the candidates, the partners will become equal owners and may decide to jointly develop and commercialize the candidate. The companies did not disclose the indications they will be researching.

 

Gene Logic will receive a success-based milestone payment for each therapeutic candidate that Organon chooses to enter into clinical development, Gene Logic said.

The Scan

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.